{"nctId":"NCT02016105","briefTitle":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","startDateStruct":{"date":"2013-12"},"conditions":["Plaque Type Psoriasis"],"count":465,"armGroups":[{"label":"GP2017 Adalimumab","type":"EXPERIMENTAL","interventionNames":["Drug: GP2017 Adalimumab"]},{"label":"Humira ® Adalimumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Humira ® Adalimumab"]}],"interventions":[{"name":"GP2017 Adalimumab","otherNames":[]},{"name":"Humira ® Adalimumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women at least 18 years of age at time of screening\n* Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization\n* Moderate to severe psoriasis as defined at baseline by:\n\n  * PASI score of 12 or greater\n  * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,\n  * Body Surface Area affected by plaque-type psoriasis of 10% or greater\n* Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Forms of psoriasis other than chronic plaque-type\n* Drug-induced psoriasis\n* Ongoing use of prohibited psoriasis treatments\n* Previous exposure to adalimumab\n* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab\n\nOther In-/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab","description":"The primary variable was the PASI75 response rate at Week 16, defined as the proportion of patients achieving a reduction of 75% or more of the PASI score at Week 16 compared with baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in PASI Score up to Week 16 (MMRM)","description":"The key secondary efficacy variable was the percentage change from baseline in PASI score at each visit up to Week 16.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.7","spread":"1.54"},{"groupId":"OG001","value":"-61.5","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Mean ATE of Percent Change From Baseline in PASI Score up to Week 16 (ANCOVA)","description":"The key secondary efficacy variable was the average treatment effect (ATE) which is the weighted average of % change from baseline in PASI scores between Week 1 and Week 16 (weights based on the time interval between two consecutive visits).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.7","spread":"1.59"},{"groupId":"OG001","value":"60.8","spread":"1.61"}]}]}]},{"type":"SECONDARY","title":"PASI 50, PASI 75, PASI 90 and PASI 100 Response Rates","description":"Proportion of patients achieving PASI 50, 75, 90 and 100 at Week 17 (end of Treatment Period 1)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"92.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null},{"groupId":"OG001","value":"44.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PASI 50, PASI75, PASI 90 and PASI100 Response Rates","description":"Proportion of Patients Achieving PASI 50, 75, 90 and 100 at Week 35 (end of Treatment Period 2)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"94.1","spread":null},{"groupId":"OG003","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"73.6","spread":null},{"groupId":"OG002","value":"70.6","spread":null},{"groupId":"OG003","value":"74.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"52.7","spread":null},{"groupId":"OG002","value":"62.7","spread":null},{"groupId":"OG003","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"30.9","spread":null},{"groupId":"OG002","value":"35.3","spread":null},{"groupId":"OG003","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"PASI 50, PASI75, PASI 90 and PASI100 Response Rates","description":"Proportion of Patients Achieving PASI 50, 75, 90 and 100 at Week 51 (Entire Study)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"93.9","spread":null},{"groupId":"OG002","value":"87.5","spread":null},{"groupId":"OG003","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"79.6","spread":null},{"groupId":"OG002","value":"75.0","spread":null},{"groupId":"OG003","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"51.0","spread":null},{"groupId":"OG002","value":"60.4","spread":null},{"groupId":"OG003","value":"62.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"29.6","spread":null},{"groupId":"OG002","value":"31.3","spread":null},{"groupId":"OG003","value":"35.1","spread":null}]}]}]},{"type":"SECONDARY","title":"IGA Response Rate","description":"Proportion of patients achieving a score of 0 (\"clear\") or 1 (\"almost clear\") or improved by at least 2 points of the IGA scale compared to baseline at Week 17.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"53.6","spread":null}]}]}]},{"type":"SECONDARY","title":"IGA Response Rate","description":"Proportion of patients achieving a score of 0 (\"clear\") or 1 (\"almost clear\") or improved by at least 2 points of the IGA scale compared to baseline at Week 51","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"58.2","spread":null},{"groupId":"OG002","value":"58.8","spread":null},{"groupId":"OG003","value":"58.8","spread":null}]}]}]},{"type":"SECONDARY","title":"IGA Response Rate","description":"Proportion of patients achieving a score of 0 (\"clear\") or 1 (\"almost clear\") or improved by at least 2 points of the IGA scale compared to baseline at Week 51","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"55.1","spread":null},{"groupId":"OG002","value":"58.3","spread":null},{"groupId":"OG003","value":"59.8","spread":null}]}]}]},{"type":"SECONDARY","title":"DLQI","description":"Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"48.4","spread":null}]}]}]},{"type":"SECONDARY","title":"DLQI","description":"Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"54.5","spread":null},{"groupId":"OG002","value":"52.9","spread":null},{"groupId":"OG003","value":"55.9","spread":null}]}]}]},{"type":"SECONDARY","title":"DLQI","description":"Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"54.2","spread":null},{"groupId":"OG003","value":"59.8","spread":null}]}]}]},{"type":"SECONDARY","title":"ADA Formation Against GP2017 Adalimumab and Humira® Adalimumab From Randomization Until Week 17","description":"Proportion of patients with at least one confirmed positive anti-drug antibodies (ADA) response to adalimumab from Randomization to Week 17.\n\nPatients with ADA positive results at baseline were excluded from subsequent results.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"34.1","spread":null}]}]}]},{"type":"SECONDARY","title":"ADA Formation Against GP2017 Adalimumab and Humira® Adalimumab From Randomization Until Week 51","description":"Proportion of patients with at least one confirmed positive anti-drug antibodies (ADA) response to adalimumab from Randomization to Week 51.\n\nPatients with ADA positive results at baseline were excluded from subsequent results.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"45.1","spread":null},{"groupId":"OG002","value":"46.7","spread":null},{"groupId":"OG003","value":"35.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":63},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Arthralgia"]}}}